MedTrace Logo

Phase 1 Study of HS-20152 in Healthy Participants

NCT07503015 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-03-31

No results posted yet for this study

Summary

This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study will evaluate the safety and tolerability of HS-20152, an investigational therapy targeting the complement pathway, in healthy adults. Secondary objectives include characterization of pharmacokinetics and pharmacodynamic effects on complement-related biomarkers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

HS-20152

HS-20152: HS-20152 will be administrated as a single dose in four sequential dose cohorts with ascending dose levels (Low, Mid, High, and an optional alternative dose cohort)

DRUG

Placebo

Placebo: Placebo matched to HS-20152 will be administrated as a single dose in each cohort, including the optional alternative dose if implemented.

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-22
Primary Completion
2027-01-01
Completion
2027-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07503015 on ClinicalTrials.gov